IP Library Granted Patent US 9,516,868
Granted Patent B2
US 9,516,868 · App. 13/195,951 · Granted Dec 13, 2016

Mice that make VL binding proteins

Inventors: Lynn Macdonald (Harrison, NY); Sean Stevens (Del Mar, CA); Cagan Gurer (Chappaqua, NY); Karolina A. Hosiawa (Yorktown Heights, NY); Andrew J. Murphy (Croton-on-Hudson, NY)
Assignee: Regeneron Pharmaceuticals, Inc.
A01K67/0278A01K67/0275C07K16/00C07K16/082C07K16/461C12N15/8509A01K2217/072A01K2227/105A01K2267/01C07K2317/21
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,516,868
App. No.
13/195,951
Granted
Dec 13, 2016
Kind
B2
Abstract

Genetically modified mice and methods for making an using them are provided, wherein the mice comprise a replacement of all or substantially all immunoglobulin heavy chain V gene segments, D gene segments, and J gene segments with at least one light chain V gene segment and at least one light chain J gene segment. Mice that make binding proteins that comprise a light chain variable domain operably linked to a heavy chain constant region are provided. Binding proteins that contain an immunoglobulin light chain variable domain, including a somatically hypermutated light chain variable domain, fused with a heavy chain constant region, are provided. Modified cells, embryos, and mice that encode sequences for making the binding proteins are provided.

Claims (16)

1. A mouse whose germline genome comprises a modified endogenous mouse immunoglobulin heavy chain locus comprising a replacement of all functional endogenous mouse immunoglobulin heavy chain variable (V H ) gene segments, all functional endogenous mouse immunoglobulin heavy chain diversity (D H ) gene segments and all functional endogenous mouse immunoglobulin heavy chain joining (J H ) gene segments at the endogenous mouse immunoglobulin heavy chain locus with a nucleotide sequence that comprises a plurality of contiguous unrearranged functional human immunoglobulin light chain variable V κ (hV κ ) gene segments and all five unrearranged functional human immunoglobulin light chain joining gene segments (hJ κ 1-hJ κ 5),

wherein the plurality of unrearranged functional hV κ gene segments and the five unrearranged functional human immunoglobulin light chain joining gene segments (hJ κ 1-hJ κ 5) are operably linked to an intact endogenous mouse immunoglobulin heavy chain constant region at the endogenous mouse immunoglobulin heavy chain locus,

wherein the plurality of unrearranged functional hV κ gene segments and the five unrearranged functional human immunoglobulin light chain joining gene segments (hJ κ 1-hJ κ 5) rearrange in a B cell during B cell development to form a rearranged human immunoglobulin light chain variable region V κ /J κ nucleotide sequence operably linked to the endogenous mouse immunoglobulin heavy chain constant region at the endogenous mouse immunoglobulin heavy chain locus, and

wherein the mouse comprises a CD19 + B cell comprising the rearranged human immunoglobulin light chain variable region V κ /J κ nucleotide sequence operably linked to the endogenous mouse immunoglobulin heavy chain constant region at the endogenous mouse immunoglobulin heavy chain locus.

2. The mouse of claim 1 , wherein all the functional endogenous mouse V H , D H , and J H gene segments are replaced with at least 6 human V κ gene segments and the five unrearranged functional human immunoglobulin light chain joining gene segments (hJ κ 1-hJ κ 5).

3. The mouse of claim 1 , wherein all the functional endogenous mouse V H , D H , and J H gene segments are replaced with at least 16 human V κ gene segments and the five contiguous unrearranged human immunoglobulin light chain joining gene segments (hJ κ 1-hJ κ 5).

4. The mouse of claim 1 , wherein all the functional endogenous mouse V H , D H , and J H gene segments are replaced with at least 30 human V κ gene segments and the five contiguous unrearranged human immunoglobulin light chain joining gene segments (hJ κ 1-hJ κ 5).

5. The mouse of claim 1 , wherein all the functional endogenous mouse V H , D H , and J H gene segments are replaced with at least 40 human V κ gene segments and the five contiguous unrearranged human immunoglobulin light chain joining gene segments (hJ κ 1-hJ κ 5).

6. An isolated cell from the mouse of claim 1 , wherein the cell comprises a modified endogenous mouse immunoglobulin heavy chain locus comprising a replacement of all functional endogenous mouse immunoglobulin heavy chain variable (V H ) gene segments, all functional endogenous mouse immunoglobulin heavy chain diversity (D H ) gene segments and all functional endogenous mouse immunoglobulin heavy chain joining (J H ) gene segments at the endogenous mouse immunoglobulin heavy chain locus with a nucleotide sequence that comprises a plurality of unrearranged functional human immunoglobulin light chain variable Vκ (hV κ ) gene segments and all five unrearranged functional human immunoglobulin light chain joining gene segments (hJ κ 1-hJ κ 5),

wherein the plurality of unrearranged functional hV κ gene segments and all five unrearranged functional human immunoglobulin light chain joining gene segments (hJ κ 1-hJ κ 5) are operably linked to an intact endogenous mouse immunoglobulin heavy chain constant region at the endogenous mouse immunoglobulin heavy chain locus,

wherein the plurality of unrearranged functional hV κ gene segments and the five unrearranged functional human immunoglobulin light chain joining gene segments (hJ κ 1-hJ κ 5) are capable of rearranging in a B cell during B cell development to form a rearranged human immunoglobulin light chain variable region V κ /J κ nucleotide sequence operably linked to the endogenous mouse immunoglobulin heavy chain constant region at the endogenous mouse immunoglobulin heavy chain locus.

7. The isolated cell of claim 6 , wherein the cell is an embryonic stem cell.

8. A cell isolated from the mouse of claim 1 , wherein the cell is the CD19 + B cell.

9. A hybridoma comprising a myeloma cell line fused with the CD19 + B cell of claim 8 , wherein the hybridoma produces a polypeptide encoded by the rearranged human immunoglobulin light chain variable region V κ /J κ nucleotide sequence operably linked to the endogenous mouse immunoglobulin heavy chain constant region.

10. The mouse of claim 1 , wherein the rearranged human immunoglobulin light chain variable region V κ /J κ gene sequence comprises at least one N addition.

11. The mouse of claim 1 , wherein the mouse is homozygous or heterozygous for the modified endogenous immunoglobulin heavy chain locus.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 5, 2012
From: MACDONALD, LYNN; STEVENS, SEAN; GURER, CAGAN; HOSIAWA, KAROLINA; MURPHY, ANDREW J.
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 027483/0973 →
Continuity (2)
Provisional Application 61369909 · Aug 2, 2010
Related Publication 20120096572A1 · Apr 19, 2012